反応式
C(Cl)(=O)C(Cl)=O.[CH3:7][O:8][CH2:9][CH:10]1[CH2:14][CH2:13][CH2:12][N:11]1[C:15]1[C:23]([CH3:24])=[CH:22][C:18]([C:19]([OH:21])=O)=[CH:17][N:16]=1.[NH2:25][S:26]([C:29]1[CH:34]=[CH:33][C:32]([C:35](=[N:37]O)[NH2:36])=[CH:31][CH:30]=1)(=[O:28])=[O:27].C(C1C=CC(S(N)(=O)=O)=CC=1)#N.CCN(C(C)C)C(C)C>>[CH3:7][O:8][CH2:9][CH:10]1[CH2:14][CH2:13][CH2:12][N:11]1[C:15]1[N:16]=[CH:17][C:18]([C:19]2[O:21][N:37]=[C:35]([C:32]3[CH:31]=[CH:30][C:29]([S:26]([NH2:25])(=[O:27])=[O:28])=[CH:34][CH:33]=3)[N:36]=2)=[CH:22][C:23]=1[CH3:24]参加物
6
反応物 5
生成物 1
実験手順
Oxalyl chloride (122 mL; 1.44 mmol), Intermediate 29 (120 mg; 0.48 mmol), 4-(aminosulfonyl)-N′-hydroxybenzenecarboximidamide, prepared as described in WO 2006/013104 A1 from 4-cyanobenzene-1-sulfonamide (ABCR; CD10716), (103 mg; 0.48 mmol, 1 eq.) and DIEA (248 mL; 1.44 mmol) were reacted according to the procedure described for Example 38. Purification by column chromatography (from cHex/EtOAc, 50/50 to EtOAc) followed by recrystallisation from DCM/n-pentane afforded the title compound as a yellow solid. LC/MS (Method A): 430.3 (M+H)+. HPLC (Method A) Rt 2.80 min (purity 93.1%).
後処理
- customwere reacted
- customPurification by column chromatography (from cHex/EtOAc, 50/50 to EtOAc)
- customfollowed by recrystallisation from DCM/n-pentane
出典と根拠
- ORDレコード
- ord-9f2657bfda694a018f714d5bbfa4d27f
- 出典データセット
- uspto-grants-2012_06
- 特許番号
- US08202865B2
関連ノート
読み込み中…